Literature DB >> 24854661

Comparative study between Ephedra sinica Stapf and Fructus Schisandrae Chinensis on ET-1 and 6-keto-prostaglandin F1α in rats with idiopathic pulmonary fibrosis.

H Q Zhai1, J R Hhang2, M C Gao3, Y Liu3, S F Zhang3, X H Wang3, F Y Meng4, Y P Wang5.   

Abstract

The aim of this study was to evaluate differences in the effects of Ephedra sinica Stapf and Fructus Schisandrae Chinensis on angiogenesis in the treatment of bleomycin-induced rat idiopathic pulmonary fibrosis. The rat models were created using bleomycin. The animals were divided into six groups: model, control, Ephedra alone, Schisandrae alone, combination of Ephedra and Schisandrae, and hydrocortisone alone. The treatments were administered for 28 days. After 7 and 28 days, the rats were sacrificed for pathological morphology examination, microvascular density determination, and angiogenesis-related cytokine examination. The Ephedra and hydrocortisone groups demonstrated significantly reduced alveolitis and pulmonary fibrosis grades compared with the model group (P < 0.05). The number of blood vessels in the Ephedra group was higher than that in the Schisandrae and combination therapy groups. At 7 days, the expression level of endothelin (ET)-1 in the model group was significantly higher than that in the normal group (P < 0.01). The level of 6-keto-prostaglandin F1α (6-keto-PGF1α) in the treatment group increased, and there were significant differences between the Ephedra group and the combination therapy and normal groups (P < 0.05). Ephedra inhibited the increase in the lung coefficient. The combination therapy prevented pulmonary artery injury and angiogenesis of the arteries by reducing the level of ET-1 and promoting the level of 6-keto-PGF1α in the blood. Ephedra and Schisandrae prevented alveolitis and the development of pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24854661     DOI: 10.4238/2014.May.13.3

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  7 in total

1.  In silico analysis and experimental validation of active compounds from fructus Schisandrae chinensis in protection from hepatic injury.

Authors:  S Y Wang; L L Fu; S Y Zhang; M Tian; L Zhang; Y X Zheng; J H Wang; J Huang; L Ouyang
Journal:  Cell Prolif       Date:  2014-12-17       Impact factor: 6.831

2.  Majie cataplasm provides a shield against asthmatic punch from the neuroimmune system.

Authors:  Wenting Ji; Xue Yu; Yushan Gao; Beida Ren; Shuang Zhang; Qingguo Wang; Xueqian Wang
Journal:  Heliyon       Date:  2020-05-23

3.  Schisandra Inhibit Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats via Suppressing M2 Macrophage Polarization.

Authors:  Zhaojuan Guo; Siru Li; Nan Zhang; Qianjun Kang; Huaqiang Zhai
Journal:  Biomed Res Int       Date:  2020-08-20       Impact factor: 3.411

4.  Utilization of Chinese medicine for respiratory discomforts by patients with a medical history of tuberculosis in Taiwan.

Authors:  Su-Tso Yang; Yi-Rong Lin; Mei-Yao Wu; Jen-Huai Chiang; Pei-Shan Yang; Te-Chun Hsia; Hung-Rong Yen
Journal:  BMC Complement Altern Med       Date:  2018-11-29       Impact factor: 3.659

Review 5.  Chinese Medicines for Preventing and Treating Radiation-Induced Pulmonary Injury: Still a Long Way to Go.

Authors:  Yan Ding; Yuechao Liu; Hongliang Li; Yong Li; Minglun Li; Ming Liu; Xianhe Wang; Fengjun Cao; Xuanbin Wang
Journal:  Front Pharmacol       Date:  2019-09-05       Impact factor: 5.810

6.  Astragaloside IV Synergizing with Ferulic Acid Ameliorates Pulmonary Fibrosis by TGF-β1/Smad3 Signaling.

Authors:  Jiahuan Tong; Zhisong Wu; Yuchen Wang; Qingxun Hao; Haoge Liu; Fang Cao; Yang Jiao
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-02       Impact factor: 2.629

7.  Combination Therapy of Wuweizi (Schisandrae Chinensis Fructus) and Dexamethasone Alleviated Dexamethasone-Induced Glucocorticoid Osteoporosis in Rats with Idiopathic Pulmonary Fibrosis.

Authors:  Zinan Qin; Siyu Li; Xiaojuan Zhang; Guoxiu Liu; Min Gu; Nan Zhang; Jiao Liu; Zhihong Ji; Keao Li; Yongpeng Han; Huaqiang Zhai
Journal:  Biomed Res Int       Date:  2020-03-19       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.